MedTrace Logo

Metabolic Effectiveness of Extracorporeal Shockwave on Abdominal Adiposity

NCT07686601 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-07-07

No results posted yet for this study

Summary

Egyptian Ministry of Health and Population's Preventive Sector, have named obesity as one of the top contributors to the national mortality and morbidity. Abdominal obesity is a strong predictor of metabolic disorders and premature mortality. Visceral fat is metabolically active and sensitive for lipolysis, unless it is more insulin resistant. It is well-known that overweight and/ or obesity is associated with overactivated proinflammatory cytokines those overactivated inflammatory process thus led to organs dysfunction across persistent low-grade inflammations . Recently, extracorporeal shock wave represents a promising, non-invasive management strategy supporting the treatment of a variety of conditions related to plastic surgery. As well, it displayed a good safety profile with no serious adverse events .

The need of this study develops from the lack in the quantitative knowledge and information regarding overall metabolic effectiveness of the Extracorporeal Shockwave on abdominal adiposity.

Conditions

  • Abdominal Obesity
  • Abdominal Obesity-Metabolic Syndrome
  • Abdominal Obesity in Young and Middle Aged Adults

Interventions

OTHER

conventional balanced, low-calorie diet 1500 k/cal for 12 weeks

conventional balanced, low-calorie diet 1500 k/cal for 12 weeks

OTHER

aerobic training program

aerobic training program along 12 weeks

OTHER

extracorporeal shockwave therapy

extracorporeal shockwave, twice weekly along 12 weeks

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Adnan AA Gharib, PHD · GOTHI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-03-01
Completion
2027-05-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07686601 on ClinicalTrials.gov